These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22890011)

  • 21. Effects of fenofibrate on lipoprotein metabolism and fatty acid distribution in Zucker rats.
    Olivier P; Plancke MO; Theret N; Marzin D; Clavey V; Fruchart JC
    Atherosclerosis; 1988 Nov; 74(1-2):15-21. PubMed ID: 3214475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.
    Sasaki J; Yamamoto K; Ageta M
    Clin Ther; 2002 Oct; 24(10):1614-26. PubMed ID: 12462290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis.
    Mackey RH; Mora S; Bertoni AG; Wassel CL; Carnethon MR; Sibley CT; Goff DC
    Diabetes Care; 2015 Apr; 38(4):628-36. PubMed ID: 25592196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives.
    Ginsberg HN
    Am J Med; 1987 Nov; 83(5B):66-70. PubMed ID: 3318456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.
    Bijland S; Pieterman EJ; Maas AC; van der Hoorn JW; van Erk MJ; van Klinken JB; Havekes LM; van Dijk KW; Princen HM; Rensen PC
    J Biol Chem; 2010 Aug; 285(33):25168-75. PubMed ID: 20501652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.
    Lefebvre AM; Peinado-Onsurbe J; Leitersdorf I; Briggs MR; Paterniti JR; Fruchart JC; Fievet C; Auwerx J; Staels B
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1756-64. PubMed ID: 9327774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome-Wide Association Study of the Postprandial Triglyceride Response Yields Common Genetic Variation in LIPC (Hepatic Lipase).
    Ibi D; Noordam R; van Klinken JB; Li-Gao R; de Mutsert R; Trompet S; Christen T; Blauw LL; van Heemst D; Mook-Kanamori DO; Rosendaal FR; Jukema JW; Dollé MET; Rensen PCN; van Dijk KW
    Circ Genom Precis Med; 2020 Aug; 13(4):e002693. PubMed ID: 32603185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.
    Tsimihodimos V; Kakafika A; Tambaki AP; Bairaktari E; Chapman MJ; Elisaf M; Tselepis AD
    J Lipid Res; 2003 May; 44(5):927-34. PubMed ID: 12611907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions.
    Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
    J Hum Genet; 2008; 53(8):709-717. PubMed ID: 18542840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
    Olivier P; Plancke MO; Marzin D; Clavey V; Sauzieres J; Fruchart JC
    Atherosclerosis; 1988 Mar; 70(1-2):107-14. PubMed ID: 3162679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia.
    Sudhop T; Lütjohann D; Ratman C; von Bergmann J; von Bergmann K
    Eur J Clin Pharmacol; 1996; 50(5):365-9. PubMed ID: 8839657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
    Yusuf N; Hidalgo B; Irvin MR; Sha J; Zhi D; Tiwari HK; Absher D; Arnett DK; Aslibekyan SW
    Pharmacogenomics; 2017 Sep; 18(14):1333-1341. PubMed ID: 28835163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
    Hiukka A; Leinonen E; Jauhiainen M; Sundvall J; Ehnholm C; Keech AC; Taskinen MR
    Diabetologia; 2007 Oct; 50(10):2067-75. PubMed ID: 17653691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol.
    Chaput E; Maubrou-Sanchez D; Bellamy FD; Edgar AD
    Lipids; 1999 May; 34(5):497-502. PubMed ID: 10380122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin and Fenofibrate Increase the Content of Unsaturated Acyl Chains in HDL and Modify In Vivo Kinetics of HDL-Cholesteryl Esters in New Zealand White Rabbits.
    Flores-Castillo C; Luna-Luna M; Carreón-Torres E; López-Olmos V; Frías S; Juárez-Oropeza MA; Franco M; Fragoso JM; Vargas-Alarcón G; Pérez-Méndez Ó
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.
    Brouillette C; Bossé Y; Pérusse L; Gaudet D; Vohl MC
    J Hum Genet; 2004; 49(8):424-432. PubMed ID: 15249972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.